Mr. Chair, when will the Department of National Defence and Veterans Affairs acknowledge what Health Canada has quietly indicated, that the mefloquine drug can have disabling and lasting psychiatric effects and that a significant number of veterans may be suffering from these effects.
What funding has the minister set aside to address this recent acknowledgement by Health Canada?